I'm LongbridgeAI, I can summarize articles.Wall Street analysts upgraded several stocks on Wednesday. Needham upgraded Similarweb and Rocket Pharmaceuticals to Buy. Wolfe Research upgraded Paychex to Peer Perform. UBS upgraded Union Pacific to Buy, raising its target to $339. Barclays upgraded Alvotech to Overweight, setting a target of $8.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Needham analyst Scott Berg upgraded Similarweb Ltd (NYSE:SMWB) from Hold to Buy and announced a price target of $11. Similarweb closed at $8.47 on Tuesday. See how other analysts view this stock.
- Wolfe Research analyst Darrin Peller upgraded Paychex Inc (NASDAQ:PAYX) from Underperform to Peer Perform. Paychex shares closed at $118.30 on Tuesday. See how other analysts view this stock.
- Needham analyst Gil Blum upgraded Rocket Pharmaceuticals Inc (NASDAQ:RCKT) from Hold to Buy and announced a $9 price target. Rocket Pharmaceuticals closed at $3.41 on Tuesday. See how other analysts view this stock.
- UBS analyst Thomas Wadewitz upgraded Union Pacific Corp (NYSE:UNP) from Neutral to Buy and raised the price target from $310 to $339. Union Pacific shares closed at $283.99 on Tuesday. See how other analysts view this stock.
- Barclays analyst Glen Santangelo upgraded Alvotech SA (NASDAQ:ALVO) from Underweight to Overweight and raised the price target from $4 to $8. Alvotech closed at $5.02 on Tuesday. See how other analysts view this stock.
Considering buying PAYX stock? Here’s what analysts think:
Photo via Shutterstock